Get the Stockscreener App
44.22
1.73%
0.75
Ultragenyx Pharmaceutical Inc stock is traded at $44.22, with a volume of 1.45M.
It is up +1.73% in the last 24 hours and down -4.70% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$43.47
Open:
$43.48
24h Volume:
1.45M
Relative Volume:
1.97
Market Cap:
$4.08B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-4.9298
EPS:
-8.97
Net Cash Flow:
$-439.53M
1W Performance:
-3.41%
1M Performance:
-4.70%
6M Performance:
+16.31%
1Y Performance:
-2.58%
1-Day Range:
$42.85
$44.45
1-Week Range:
$41.45
$46.75
52-Week Range:
$37.02
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
44.22 | 4.08B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Franklin Resources Inc. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ultragenyx Awards Key Employee Stock Grants: 15,175 RSUs Distributed in Strategic Talent Acquisition - StockTitan
RARE Submits BLA To The FDA For Sanfilippo Syndrome Gene Therapy - Barchart
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy - Zacks Investment Research
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $88.00 Price Target at Wells Fargo & Company - MarketBeat
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 11 Analysts - Benzinga
Geode Capital Management LLC Buys 65,623 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx seeks FDA nod for Sanfilippo A gene therapy By Investing.com - Investing.com Canada
NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible - GlobeNewswire
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome - GlobeNewswire
Ultragenyx Launches Pivotal Phase 3 Trial for Breakthrough Angelman Syndrome Treatment GTX-102 - StockTitan
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Ultragenyx seeks FDA nod for Sanfilippo A gene therapy - Investing.com
Ultragenyx Submits Biologics License Application to the - GlobeNewswire
Ultragenyx Seeks FDA Approval for Groundbreaking Sanfilippo Syndrome Gene Therapy - StockTitan
Ultragenyx Pharmaceutical Inc. Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) - Marketscreener.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
State Street Corp Has $147.99 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical's SWOT analysis: rare disease biotech stock at crossroads - Investing.com
Y Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Janus Henderson Group PLC Sells 35,200 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Hypophosphatasia Market Expected to Experience Major Growth by 2034, According to DelveInsight | PuREC, AstraZeneca, Ultragenyx Pharma Inc., Alexion - The Globe and Mail
Hypophosphatasia Market Expected to Experience Major Growth - openPR
Frazier Life Sciences Management L.P. Purchases 208,715 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
CDKL5 Deficiency Disorder Pipeline 2024: Clinical Trials - openPR
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Wellington Management Group LLP - MarketBeat
BNP Paribas Financial Markets Sells 38,641 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Opinion: What Accelerated Approval’s Naysayers Miss - BioSpace
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Reduced by Jacobs Levy Equity Management Inc. - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Point72 Asset Management L.P. - MarketBeat
Point72 DIFC Ltd Has $806,000 Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
(RARE) On The My Stocks Page - Stock Traders Daily
Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Australia
RTW Investments LP Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Possible Bearish Signals With Ultragenyx Pharmaceutical Insiders Disposing Stock - Simply Wall St
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Lessened by Cinctive Capital Management LP - MarketBeat
Bamco Inc. NY Purchases New Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Erste Asset Management GmbH Makes New Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Verition Fund Management LLC Reduces Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Charles Schwab Investment Management Inc. - MarketBeat
Cerity Partners LLC Invests $1.77 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Baker BROS. Advisors LP Has $87.55 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Capstone Investment Advisors LLC Purchases Shares of 13,089 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Vestal Point Capital LP Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Suvretta Capital Management LLC Sells 910,112 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Alkeon Capital Management LLC Boosts Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Acuta Capital Partners LLC Purchases New Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx to Participate in Investor Conferences in December - GlobeNewswire
Ultragenyx to Present at Three Major Healthcare Investor Conferences in December | RARE Stock News - StockTitan
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):